Advancing the development of tuberculosis therapy

Nature Reviews Drug Discovery volume 11, pages171–172(2012)Cite this article

Subjects

Abstract

Although the development of novel drugs and combination regimens for tuberculosis has accelerated in recent years, the pipeline remains thin and major challenges remain to be addressed in efficiently evaluating newer drugs to improve treatment outcomes, shorten duration of therapy and tackle drug resistance.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

References

  1. 1

    World Health Organization. Global tuberculosis control 2011. WHO website [online], (WHO, Geneva, Switzerland, 2011).

  2. 2

    World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO website [online], (WHO, Geneva, Switzerland, 2012).

  3. 3

    Orenstein, E. W. et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis. 9, 153–161 (2009).

  4. 4

    STOP TB Partnership. Working group on new TB drugs discovery portfolio. New TB Drugs website [online], (2011).

  5. 5

    Phillips, P. et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J. Infect. Dis. (in the press).

Download references

Author information

Affiliations

  1. Alimuddin Zumla is at the Division of Infection and Immunity, University College London, London NW3 2PF, UK.
    • Alimuddin Zumla
  2. Richard Hafner is at the National Institute for Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland 20892, USA.
    • Richard Hafner
  3. Christian Lienhardt is at the Stop TB Partnership, 20 avenue Appia 1211, World Health Organization, Geneva 27, Switzerland.
    • Christian Lienhardt
  4. Michael Hoelscher is at the Division of Infectious Diseases and Tropical Medicine, University of Munich, Leopoldstraße 5, 80802 Munich, Germany.
    • Michael Hoelscher
  5. Andrew Nunn is at the Medical Research Council, 222 Euston Road, London NW1 2DA, UK.
    • Andrew Nunn
Authors
  1. Search for Alimuddin Zumla in:
  2. Search for Richard Hafner in:
  3. Search for Christian Lienhardt in:
  4. Search for Michael Hoelscher in:
  5. Search for Andrew Nunn in:

Corresponding author

Correspondence to Alimuddin Zumla.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zumla, A., Hafner, R., Lienhardt, C. et al. Advancing the development of tuberculosis therapy. Nat Rev Drug Discov 11, 171–172 (2012) doi:10.1038/nrd3694

Download citation

Further reading